

# ERROR CORRECTION FORM

Sequence Number:

CIBMTR Recipient ID:

Initials:

Today's Date:

Infusion Date:

CIBMTR Center Number:

## Form 3500 R2.0: Subsequent Neoplasms

Center: \_\_\_\_\_ CRID: \_\_\_\_\_

### Key Fields

Sequence Number: \_\_\_\_\_

Date Received: \_\_\_\_-\_\_\_\_-\_\_\_\_

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Research ID: \_\_\_\_\_

Event date: \_\_\_\_-\_\_\_\_-\_\_\_\_

### New Malignancy, Lymphoproliferative or Myeloproliferative Disease / Disorder

Questions: 1 - 12

**A separate form 3500 must be submitted to report each new malignancy diagnosed since the date of last report. The submission of a pathology report or other supportive documentation for each reported new malignancy is strongly recommended.**

1 Specify the new malignancy

**Hematologic Malignancy**

- Acute myeloid leukemia (AML / ANLL)
- Acute lymphoblastic leukemia (ALL)
- Other leukemia
- Myelodysplastic syndrome (MDS)
- Myeloproliferative neoplasm (MPN)
- Overlapping myelodysplasia / myeloproliferative neoplasm (MDS / MPN)
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Multiple myeloma / plasma cell neoplasms
- Clonal cytogenetic abnormality without leukemia or MDS
- Uncontrolled proliferation of donor cells without malignant transformation

**Solid Tumors**

- Bone sarcoma (*regardless of site*)
- Soft tissue sarcoma (*regardless of site*)
- Oropharyngeal cancer (*e.g. tongue, mouth, throat*)
- Gastrointestinal malignancy (*e.g. esophagus, stomach, small intestine, colon, rectum, anus, liver, pancreas*)
- Lung cancer
- Melanoma
- Squamous cell skin malignancy
- Basal cell skin malignancy
- Breast cancer
- Genitourinary malignancy (*e.g. kidney, bladder, cervix, uterus, ovary, prostate, testis*)
- Central nervous system (CNS) malignancy (*e.g. meningioma, glioma*)
- Thyroid cancer

**Other**

- Other new malignancy

2 Was post-transplant lymphoproliferative disorder (PTLD) diagnosed?

- Yes  No

3 Specify type of PTLD

- Monomorphic  Polymorphic  Unknown

4 Specify oropharyngeal cancer

- Tongue  Mouth  Throat  Other oropharyngeal cancer

Mail, fax or email this form to Minneapolis. Fax: 612-627-5895. Email: scanform@nmdp.org.  
Retain the original form at the transplant center.

# ERROR CORRECTION FORM

Sequence Number:

CIBMTR Recipient ID:

Initials:

Today's Date:

 20   
Month Day Year

Infusion Date:

 20   
Month Day Year

CIBMTR Center Number:

  
Month Day Year

## Form 3500 R2.0: Subsequent Neoplasms

Center:

CRID:

### 5 Specify gastrointestinal malignancy

- Esophagus  
 Stomach  
 Small intestine (*duodenum, jejunum, ileum*)  
 Colon  
 Rectum  
 Anus  
 Liver  
 Pancreas  
 Other gastrointestinal malignancy

### 6 Specify genitourinary malignancy

- Kidney  Bladder  Cervix  Uterus  Ovary  Prostate  Testis  Other genitourinary malignancy

### 7 Specify CNS malignancy

- Meningioma  Glioma  Other CNS malignancy

### 8 Specify other new malignancy: \_\_\_\_\_

9 Date of diagnosis: \_\_\_\_ - \_\_\_\_ - \_\_\_\_

10 Was documentation submitted to the CIBMTR? (e.g. pathology report, autopsy report) (CIBMTR recommends attaching documentation)

- Yes  No

11 Was the new malignancy donor / cell product derived?

- Yes  No  Not done

12 Was documentation submitted to the CIBMTR? (e.g. cell origin evaluation (VNTR, cytogenetics, FISH)) (CIBMTR recommends attaching documentation)

- Yes  No

## Post-Transplant Lymphoproliferative Disorder

Questions: 13 - 24

13 Was PTLN confirmed by biopsy?

- Yes  No

14 Was the pathology of the tumor EBV positive?

- yes  no

15 Was documentation submitted to the CIBMTR? (e.g. pathology report) (CIBMTR recommends attaching documentation)

- Yes  No

16 Was there EBV reactivation in the blood?

- Yes  No  Not done

17 How was EBV reactivation diagnosed?

- Qualitative PCR of blood  
 Quantitative PCR of blood  
 Other method

18 Specify other method: \_\_\_\_\_

19 Quantitative EBV viral load of blood: (at diagnosis of EBV) \_\_\_\_\_ copies/mL

20 Was a quantitative PCR of blood performed again after diagnosis?

- Yes  No

21 Highest EBV viral load of blood: \_\_\_\_\_ copies/mL

22 Was there lymphomatous involvement? (e.g. a mass)

- Yes  No

Mail, fax or email this form to Minneapolis. Fax: 612-627-5895. Email: scanform@nmdp.org.  
Retain the original form at the transplant center.

# ERROR CORRECTION FORM

Sequence Number:

CIBMTR Recipient ID:

Initials:

Today's Date:

Infusion Date:

CIBMTR Center Number:

## Form 3500 R2.0: Subsequent Neoplasms

Center: \_\_\_\_\_ CRID: \_\_\_\_\_

**23** Specify sites of PTLD involvement (*check all that apply*)

- Bone marrow
- Central nervous system (*brain or cerebrospinal fluid*)
- Liver
- Lung
- Lymph nodes
- Spleen
- Other site

**24** Specify other site: \_\_\_\_\_

First Name: \_\_\_\_\_

Last Name: \_\_\_\_\_

E-mail address: \_\_\_\_\_

Date: \_\_\_\_\_

Mail, fax or email this form to Minneapolis. Fax: 612-627-5895. Email: [scanform@nmdp.org](mailto:scanform@nmdp.org).  
Retain the original form at the transplant center.